Nov 2026· Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova· Vol 126 10. Vyp. 2, pp.
33-40
· 0 citations· 57 references
Medicine
TL;DR
This systematic review synthesizes current evidence on molecular biomarkers of MSA in biological fluids, including cerebrospinal fluid and blood plasma, and critically assesses their pathophysiological relevance, differential diagnostic and prognostic value, and the limitations and inconsistencies that hinder clinical implementation.
Abstract
Multiple system atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder. Early diagnosis remains challenging because of clinical heterogeneity and symptom overlap with Parkinson's disease and other atypical parkinsonian syndromes. This systematic review synthesizes current evidence on molecular biomarkers of MSA in biological fluids, including cerebrospinal fluid and blood plasma, following PRISMA 2020 guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). It evaluates seven groups of potential biomarkers: aggregated α-synuclein, neurofilament light chains, tau protein, myelin basic protein, neurotransmitters (dopamine, norepinephrine, serotonin, β-endorphins), neuroinflammation markers (cytokines, c), homocysteine, and coenzyme Q10. The review critically assesses their pathophysiological relevance, differential diagnostic and prognostic value, and the limitations and inconsistencies that hinder clinical implementation. It also discusses promising strategies for combining biomarkers.
Alzheimer’s disease (AD) and Parkinson’s disease (PD) together affect over 65 million people worldwide, yet no disease-modifying treatment exists for either condition. For decades, they were studied as separate entities, involving different proteins, different brain regions, and different clinical teams. Blood- based b...
Shiven Bansal· Journal of High School Resea...· 0 citations
It is suggested that CSF neuroinflammatory biomarkers were not associated with early motor severity in this sample of early-stage PD patients, and future research should examine whether these markers are more closely associated with other domains such as cognitive decline.
Harshal Lingineni· American Journal of Student...· 0 citations
BACKGROUND
Parkinson's disease (PD) is frequently accompanied by neuropsychiatric symptoms (NPS), including cognitive impairment, which often emerge early and co-occur. Their long-term evolution remains incompletely characterized, particularly in biomarker-positive cohorts.
OBJECTIVE
The aim was to examine the evolut...
Izabelle Schoen, Jing Wang, Sharon X. Xie et al.· Movement Disorders· 0 citations
Background: Alzheimer’s disease (AD) is characterized by extracellular amyloid-beta accumulation and intracellular neurofibrillary tangles composed of hyperphosphorylated tau, changes that precede cognitive decline by years. Although diagnostic methods have advanced, gold-standard techniques such as positron emission t...
Eduarda Viana Silva, Iury Hélder Santos Dantas, Ingrid Yasmim Farias de Melo Yasmim Farias de Melo et al.· ANPAbstract_CBN26· 0 citations
Dopamine transporter (DAT) imaging and α-synuclein seed amplification assay (SAA) are biomarkers for Lewy body disease (LBD). We aimed to identify clinical and biomarker factors associated with SAA positivity in patients with cognitive impairment and frequent motor parkinsonism. Dual-phase DAT positron emission tomogra...
Byoung Seok Ye, Lawren VandeVrede, Su-Hee Jeon et al.· Parkinsonism & Related Disor...· 0 citations
Multimodal fusion architectures, particularly cross-attention transformers integrating motor, voice, and gait data, consistently outperformed unimodal approaches by 4%-8% in the area under the receiver operating characteristic curve (AUC), with the largest gains in early stage detection and differential diagnosis tasks...
Muhammad Imran Khan, A. Imran, A. Alshammari· Computational biology and ch...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.